Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must meet all of the following inclusion criteria within 28 days prior to the baseline visit:~  1. The ability to understand and sign a written informed consent form, prior to participation in any screening procedures and must be willing to comply with all study requirements~ 2. Male or non-pregnant, non-lactating females~ 3. Between 18 to 65 years, inclusive~ 4. Body Mass Index (BMI) of 18 to 35 kg/m2, inclusive.~ 5. Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for a period of at least 1 month after the study~Exclusion Criteria:~1. Any significant acute or chronic medical illness~2. Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations~3. Positive blood screen for hepatitis B core and/or C antibodies and/or hepatitis B surface antigen~4. Positive blood screen for HIV-1 and/or 2 antibodies~5. Current or recent (within 3 months) gastrointestinal disease~6. Clinically relevant alcohol or drug use (positive urine drug screen) or history of alcohol or drug use considered by the Investigator to be sufficient to hinder compliance with treatment, follow-up procedures or evaluation of adverse events. Smoking is permitted, but tobacco intake should remain consistent throughout the study~7. Exposure to any investigational drug or placebo within 3 months of first dose of study drug~8. Consumption of grapefruit, or Seville oranges or any grapefruit or Seville orange containing product within one week of first dose of study drug and for the duration of the study~9. Use of any other drugs, including over-the-counter medications and herbal preparations, within two weeks prior to first dose of study drug, unless approved/prescribed by the Principal Investigator as known not to interact with study drugs.~10. Females of childbearing potential without the use of effective non-hormonal birth control methods, or not willing to continue practising these birth control methods for at least 30 days after the end of the treatment period~11. Previous allergy to any of the constituents of the pharmaceuticals administered in this trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- LPV/r 400/100 mg (Type: ACTIVE_COMPARATOR): Lopinavir/ritonavir 400/100 mg twice daily (2 heat-stable 200/50 mg tablets twice daily (BID))
- LPV/r 200/150 mg (Type: EXPERIMENTAL): Lopinavir/ritonavir 200/150 mg twice daily (1 heat-stable 200/50 mg tablet BID plus 1 ritonavir 100 mg capsule BID)
- LPV/r 200/50 mg (Type: EXPERIMENTAL): Lopinavir/ritonavir 200/50 mg twice daily (1 heat-stable 200/50 mg tablet BID)

Based on this trial design, predict the completion outcome and termination type (if applicable).